NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc.

NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN VIATRIS INC. (VTRS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term ...

We recently published an article titled Why These 15 Large-Cap Stocks Are Plunging So Far In 2025. In this article, we are ...

Viatris emerged from Pfizer's merger with Mylan and Upjohn, trading since 2020, with a market cap of $11 billion. See why I ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

Random Walk Theory is wrong. If price were random, there would not be support or resistance levels. The Viatris (VTRS) shows there are.

With an average analyst rating of hold, Viatris is clearly not a favorite. But some of the best stock picks are contrarian in ...

Its shares falling by -13.1% today, Viatris seems to be confirming what most analysts are saying about the stock. Despite its ...

It follows the firm’s belated filing of its annual report. Viatris (VTRS) stock fell 15.2% after the pharmaceutical firm issued weaker-than-expected earnings and a disappointing outlook.

Viatris missed Q4 estimates with an 8% revenue decline. 2025 guidance falls short as FDA import alert hits sales. Share ...